Cytochrome bd oxidase: An emerging anti-tubercular drug target

P Saha, S Das, HK Indurthi, R Kumar, A Roy… - RSC Medicinal …, 2024 - pubs.rsc.org
Cytochrome bd (Cyt-bd) oxidase, one of the two terminal oxidases in the Mycobacterium
tuberculosis (Mtb) oxidative phosphorylation pathway, plays an indispensable role in …

A systematic review of economic evaluations of active tuberculosis treatments

JY Byun, HL Kim, EK Lee, SH Kwon - Frontiers in Pharmacology, 2021 - frontiersin.org
Background: The disease burden of active tuberculosis (TB) is considerable, but systematic
reviews of economic evaluations of active TB treatments are scarce. Methods: PubMed …

2-Mercapto-Quinazolinones as Inhibitors of Type II NADH Dehydrogenase and Mycobacterium tuberculosis: Structure–Activity Relationships, Mechanism of Action …

D Murugesan, PC Ray, T Bayliss… - ACS infectious …, 2018 - ACS Publications
Mycobacterium tuberculosis (MTb) possesses two nonproton pumping type II NADH
dehydrogenase (NDH-2) enzymes which are predicted to be jointly essential for respiratory …

A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets

LE Via, K England, DM Weiner, D Schimel… - Antimicrobial agents …, 2015 - Am Soc Microbiol
Shortening the lengthy treatment duration for tuberculosis patients is a major goal of current
drug development efforts. The common marmoset develops human-like disease pathology …

Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis

NC Ammerman, RV Swanson… - Antimicrobial agents …, 2018 - Am Soc Microbiol
The antileprosy drug clofazimine was recently repurposed as part of a newly endorsed short-
course regimen for multidrug-resistant tuberculosis. It also enables significant treatment …

Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis

GB Gomez, DW Dowdy, ML Bastos, A Zwerling… - BMC infectious …, 2016 - Springer
Background Despite improvements in treatment success rates for tuberculosis (TB), current
six-month regimen duration remains a challenge for many National TB Programmes, health …

Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial

M Milstein, L Lecca, C Peloquin, D Mitchison… - BMC Infectious …, 2016 - Springer
Background Evidence has existed for decades that higher doses of rifampin may be more
effective, but potentially more toxic, than standard doses used in tuberculosis treatment …

Treatment-shortening effect of a novel regimen combining clofazimine and high-dose rifapentine in pathologically distinct mouse models of tuberculosis

V Saini, NC Ammerman, YS Chang… - Antimicrobial agents …, 2019 - Am Soc Microbiol
Clofazimine and high-dose rifapentine have each separately been associated with treatment-
shortening activity when incorporated into tuberculosis (TB) treatment regimens. We …

A systematic review of economic evaluations of pharmacological treatments for active tuberculosis

S Nagar, D Nicholls, D Dawoud - Frontiers in Public Health, 2024 - frontiersin.org
Objectives The continuing spread of tuberculosis (TB) worldwide, especially drug-resistant
TB, poses a major challenge to healthcare systems globally. Addressing this requires …

The impact and cost-effectiveness of a four-month regimen for first-line treatment of active tuberculosis in South Africa

GM Knight, GB Gomez, PJ Dodd, D Dowdy… - PLoS …, 2015 - journals.plos.org
Background A 4-month first-line treatment regimen for tuberculosis disease (TB) is expected
to have a direct impact on patient outcomes and societal costs, as well as an indirect impact …